For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

This could start to bring down the cost of brand-name competitors—here's who may get to use it, and one major difference from ...

The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

The fight against type 2 diabetes just reached a groundbreaking milestone. Last week, the U.S. Food and Drug Administration ...

Liraglutide is under clinical development by Novo Nordisk and currently in Phase III for Obesity. According to GlobalData, Phase III drugs for Obesity have a 44% phase transition success rate (PTSR) ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals) ...

The generic of Victoza, developed by the U.K.'s Hikma Pharmaceuticals ... The GLP-1 hormone in the human body promotes the ...

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...